Medscape Conference Coverage, based on selected sessions at the:

33rd European Society for Medical Oncology (ESMO) Congress

September 12 - 16, 2008; Stockholm, Sweden

This activity is not sanctioned by, nor a part of, the European Society for Medical Oncology. Conference news does not receive grant support and is produced independently.

Conference News

  • Antithrombic Prophylaxis for All Cancer Patients?

    Cancer patients have a higher incidence of venous thromboembolism than the general population, but experts do not agree on whether all cancer patients should receive prophylactic therapy.
    Medscape Medical News, September 23, 2008
  • Melanoma Risk and Gene Related to Vitamin D

    A naturally occurring variant of a gene involved in vitamin D metabolism appears to be associated with an increased risk for skin cancer.
    Medscape Medical News, September 22, 2008
  • Novel Agents Potentially Beneficial in Recurrent Ovarian Cancer

    Two novel agents exhibited antitumor activity in women with recurrent ovarian cancer and hold promise as effective second-line treatments.
    Medscape Medical News, September 19, 2008
  • Maintenance Therapy in Metastatic Breast Cancer

    A pegylated-liposomal doxorubicin formulation offers a low-toxicity option for maintenance therapy in metastatic breast cancer, say Spanish researchers.
    Medical Medscape News, September 18, 2008
  • Docetaxel Improves Early Breast Cancer Outcome

    Incorporating docetaxel into a sequential regimen of epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil improved recurrence-free and overall survival in women with node-positive early-stage breast cancer.
    Medscape Medical News, September 16, 2008
  • Temozolomide No Better Than Dacarbazine

    One of the largest trials to date of advanced melanoma found no improvement over standard dacarbazine treatment; a separate study reveals a gene variant that increases the for melanoma by 80%.
    Medscape Medical News, September 16, 2008
  • New Drug Shows Promise in Pancreatic Cancer

    The experimental product EndoTAG-1, which contains paclitaxel in cationic liposomes, improved survival over the standard therapy, gemcitabine.
    Medscape Medical News, September 16, 2008
  • Gefitinib Therapy in Asian Lung Cancer Patients

    A large study from Asia shows that gefitinib was superior to chemotherapy in selected patients, and so could be considered a potential first-line treatment.
    Medscape Medical News, September 15, 2008
  • Pazopanib and Early-Stage Lung Cancer

    Pazopanib used as preoperative monotherapy reduced tumor size in 86% of early-stage lung cancer patients, and was well tolerated and had limited toxicity.
    Medscape Medical News, September 15, 2008
  • Alternating Treatment Regimen Shows Promise

    An alternating treatment regimen of chemotherapy and radiotherapy in patients with locally advanced head and neck cancer has fewer toxicities than a concurrent regimen, and was associated with a high rate of response.
    Medscape Medical News, September 15, 2008
  • IV Iron for Chemotherapy-Induced Anemia

    Another study has shown that adding intravenous iron to an erythropoiesis-stimulating agent can improve on the results, with potential cost savings, and the researcher urges all oncologists to consider such treatment.
    Medscape Medical News, September 15, 2008
  • Preventing Chemotherapy-Induced Emesis

    Palonosetron was superior in inducing an overall complete response rate and in preventing delayed-phase nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Medscape Medical News, September 14, 2008
  • Targeted Therapies for Renal Cancer and GIST

    The prognosis for patients with metastatic renal cell carcinoma and advanced gastrointestinal stromal tumors has improved with targeted therapies, but challenges remain as far as outcomes, patient compliance, and defining the most optimal strategies.
    Medscape Medical News, September 13, 2008
  • EGFR Mutations in NSCLC and Erlotinib

    Among patients with stage 4 non-small-cell lung cancer who were positive for EGFR mutations, erlotinib was shown to increase overall survival.
    Medscape Medical News, September 13, 2008
Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the 2008 Breast Cancer Symposium. These materials and the related activity are not sanctioned by the 2008 Breast Cancer Symposium or the commercial supporter of the conference and do not constitute an official part of that conference.